Evidence mapPaperPMID 38112643Full record

ArticleCancer research communications2024

WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers.

Joseph L Sottnik, Madeleine T Shackleford, Sydney K Robinson, Fabian R Villagomez, Shaymaa Bahnassy, Steffi Oesterreich, Junxiao Hu, Zeynep Madak-Erdogan, Rebecca B Riggins, Bradley R Corr and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Joseph L Sottnik *Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-0263-3608
Madeleine T Shackleford *Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-2599-1747
Sydney K RobinsonDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0009-0000-1809-8577
Fabian R VillagomezDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-4510-1329
Shaymaa BahnassyDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia.ORCID 0000-0001-9882-4195
Steffi OesterreichDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-2537-6923
Junxiao HuBiostatistics and Bioinformatics Shared Resource, University of Colorado Cancer Center, Aurora, Colorado.ORCID 0000-0002-5937-7916
Zeynep Madak-ErdoganDepartment of Food Science and Human Nutrition, Cancer Center at Illinois, Division of Nutritional Sciences, University of Illinois Urbana-Champaign, Champaign, Illinois.ORCID 0000-0003-2607-1643
Rebecca B RigginsDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia.ORCID 0000-0002-1555-4431
Bradley R CorrDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-6608-2585
Linda S CookDepartment of Epidemiology, University of Colorado School of Public Health, Aurora, Colorado.ORCID 0000-0001-8641-0710
Lindsey S TreviñoDepratment of Population Sciences, Division of Health Equities, City of Hope, Duarte, California.ORCID 0000-0003-3810-4895
Benjamin G Bitler *Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-5809-5271
Matthew J Sikora *Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-2915-7442
University of Colorado Anschutz Medical Campus · USGeorgetown University · USCity of Hope · USColorado School of Public Health · USUniversity of Colorado Cancer Center · USUniversity of Illinois Urbana-Champaign · USUniversity of Pittsburgh · US

Funding

University of Colorado Cancer Center Support GrantP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · 1988 to 2025
$33.7M
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparitiesR01CA285446 · UNIVERSITY OF COLORADO DENVER · 2025 to 2025
$595k
Targeting Wnt signaling in therapy-resistant ovarian cancerR37CA261987 · UNIVERSITY OF COLORADO DENVER · 2025 to 2025
$442k
NCI NIH HHS P30 CA046934NCI NIH HHS R00 CA193734NCI NIH HHS R01 CA285446NCI NIH HHS R37 CA261987NIH HHS S10 OD025267ODCDC CDC HHS S10 OD025267
6 · The paper itself

Abstract

Wnt ligand WNT4 is critical in female reproductive tissue development, with WNT4 dysregulation linked to related pathologies including breast cancer (invasive lobular carcinoma, ILC) and gynecologic cancers. WNT4 signaling in these contexts is distinct from canonical Wnt signaling yet inadequately understood. We previously identified atypical intracellular activity of WNT4 (independent of Wnt secretion) regulating mitochondrial function, and herein examine intracellular functions of WNT4. We further examine how convergent mechanisms of WNT4 dysregulation impact cancer metabolism. In ILC, WNT4 is co-opted by estrogen receptor α (ER) via genomic binding in WNT4 intron 1, while in gynecologic cancers, a common genetic polymorphism (rs3820282) at this ER binding site alters WNT4 regulation. Using proximity biotinylation (BioID), we show canonical Wnt ligand WNT3A is trafficked for secretion, but WNT4 is localized to the cytosol and mitochondria. We identified DHRS2, mTOR, and STAT1 as putative WNT4 cytosolic/mitochondrial signaling partners. Whole metabolite profiling, and integrated transcriptomic data, support that WNT4 mediates metabolic reprogramming via fatty acid and amino acid metabolism. Furthermore, ovarian cancer cell lines with rs3820282 variant genotype are WNT4 dependent and have active WNT4 metabolic signaling. In protein array analyses of a cohort of 103 human gynecologic tumors enriched for patient diversity, germline rs3820282 genotype is associated with metabolic remodeling. Variant genotype tumors show increased AMPK activation and downstream signaling, with the highest AMPK signaling activity in variant genotype tumors from non-White patients. Taken together, atypical intracellular WNT4 signaling, in part via genetic dysregulation, regulates the distinct metabolic phenotypes of ILC and gynecologic cancers. SIGNIFICANCE: WNT4 regulates breast and gynecologic cancer metabolism via a previously unappreciated intracellular signaling mechanism at the mitochondria, with WNT4 mediating metabolic remodeling. Understanding WNT4 dysregulation by estrogen and genetic polymorphism offers new opportunities for defining tumor biology, precision therapeutics, and personalized cancer risk assessment.

Indexed as

Breast NeoplasmsGenital Neoplasms, FemaleAMP-Activated Protein KinasesCarbonyl Reductase (NADPH)FemaleHumansLigandsSignal TransductionWnt4 ProteinAMP-Activated Protein KinasesCarbonyl Reductase (NADPH)DHRS2 protein, humanLigandsWnt4 ProteinWNT4 protein, human

Identifiers

PMID38112643
PMCPMC10793200
OpenAlexW4389936199

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.